Clinical data for Episealer® accepted for podium presentation at a European scientific congress

Episurf Medical (Nasdaq: EPIS B) today announces that the scientific abstract “Patient specific mini-metal implants. The future of cartilage repair for the right patient?” by Dr. med. J. Holz et al. has been accepted for a podium presentation at the ESSKA (European Society for Sports Traumatology, Knee Surgery and Arthroscopy) Speciality Days in Madrid, Spain, which will take place on November 8-9, 2019. The abstract focuses on clinical outcomes for patients in the “gap age”, 35-60 years old, that have undergone treatment of focal chondral defects using the mini-metal implant Episealer®.

The abstract shows excellent early clinical results from the treatment of focal symptomatic cartilage lesions on the femoral condyles or trochlea area of the knee with an individualised implant.

"ESSKA is an important organisation for the global knee industry. The fact that clinical results from an ongoing European clinical trial of the Episealer® are presented at a podium presentation during their speciality days 2019 is a great milestone for us. It also says something about the ever-increasing interest in our implant technology that we are experiencing. This is the right forum for us, and we continue to make great progress”, says Pål Ryfors, CEO of Episurf Medical.

For more information, please contact:

Pål Ryfors, CEO, Episurf Medical
Tel:+46 (0) 709 62 36 69
Email: pal.ryfors@episurf.com

About Episurf Medical

Episurf Medical is endeavoring to bring people with painful joint injuries a more active, healthier life through the availability of minimally invasive and individualised treatment alternatives. Episurf Medical’s Episealer® individualised implants and Epiguide® surgical drill guides are developed for treating localised cartilage injury in joints. Episurf Medical’s μiFidelity® system enables implants to be cost-efficiently tailored to each individual’s unique injury for the optimal fit and minimal intervention. Episurf Medical’s head office is in Stockholm, Sweden. Its share (EPIS B) is listed on Nasdaq Stockholm. For more information, go to the company’s website: www.episurf.com.

Tags:

About Us

Episurf Medical is endeavoring to bring people with painful joint injuries a more active, healthier life through the availability of minimally invasive and personalized treatment alternatives. Episurf Medical’s Episealer® personalized implants and Epiguide® surgical drill guides are developed for treating localized cartilage injury in joints. Episurf Medical’s μiFidelity® system enables implants to be cost-efficiently tailored to each individual’s unique injury for the optimal fit and minimal intervention. Episurf Medical’s head office is in Stockholm, Sweden. Its share (EPIS B) is listed on Nasdaq Stockholm. For more information, go to the company’s website: www.episurf.com.